ASCI
You are here: Skip Navigation LinksHome > HCP

Patient website

Website dedicated to help patients, their family and friends about the cancer immunotherapeutic approach in an easy-to-understand format.

Visit Patient website

MAGRIT trial

Website providing information about the now recruiting Non-Small Cell Lung Cancer phase III clinical study

www.ascitrials.com

ASCI is a new, Antigen Specific Cancer Immunotherapy approach

Welcome to the ASCI website dedicated to healthcare professionals

Antigen Specific Immunotherapeutics or ASCI is a novel approach to cancer treatment that aims at treating cancer through the targeting of cancer-specific antigens.

ASCI aims to re-stimulate the patients own immune response to selectively destroy tumor cells and is currently being evaluated in a large scale Phase III for the adjuvant treatment of Non-Small Cell Lung Carcinoma.
Learn more about the ASCI science and the targeted cancer types

Cancer is the result of the patient's immune system that has failed to eliminate cancerous cells. Cancer immunotherapy builds on the presence of various types of cancer antigens and encompasses a range of different specific and non-specific approaches and techniques that aims at stimulating and enhancing the natural immune response to malignant cells to ultimately destroy them.

Discover the anti-cancer immune response, cancer-antigens and the different types of cancer immunotherapy

New user?

Welcome to www.gsk-asci.com

If this is your first time at this site, please click here to register.

Register now

Why register?

For legal reasons, this page is intended solely for healthcare professionals. This is why we ask you to register.

Last update: 27-May-2009
ASCIs are investigational compounds